Aim: This retrospective study was undertaken to analyze the outcome of hepatic resection in hepatocellular carcinomas (HCCs) that shrunk after transcatheter hepatic arterial chemoembolization (TACE) in 65 patients with unresectable HCCs between June 1987 and September 1996. Materials and Methods: Among these 65 patients, the median diameter of the tumor was 9.9 cm (5.6–20.0) prior to the first TACE, after 1–6 times of TACE (median 3) the median tumor diameter reduced to 3.7 cm (1.9–12.5) prior to resection. The duration between the last TACE treatment and sequential resection varied from 1 to 9 months (median 2.5). Serum α-fetoprotein (AFP) levels were abnormal in 39 out of the 65 patients. In AFP producing HCCs, the AFP level returned to normal (≤20 µg/l) in 14 out of 39 patients (35.9%). Hepatic segmentectomy, multiple hepatic segmentectomy or partial hepatic resection were performed in 61 patients, right hemihepatectomy in 1, left trisegmentectomy in 2, and left hemihepatectomy in 1. Results: Tumor necrosis ranged from 40 to 100% and pathologically and complete tumor necrosis occurred in 11 patients (16.9%). Of 14 patients with AFP levels decreased to normal, 10 still had microscopic living tumor foci. The 1-, 3- and 5-year survival rates of the 65 patients were 80.0, 65.0 and 56.0% respectively. Conclusion: TACE treatment can provide a chance of tumor resection for those patients with initially judged unresectable HCCs, and liver resection should be performed when the tumor has shrunk to be resectable, even when the AFP level has returned to normal.

Keywords:
Liver cancer, Hepatocellular carcinoma, Chemoembolization, Staged resection
1.
Yamada R, Kishi K, Sato M, Sonomura T, Nishida N, Taraka K, Shioyama Y, Terada M, Kimura M: Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. World J Surg 1995;19:795–800.
2.
Liu Q, Jia YC, Tian JM, Wang ZT, Ye H, Lu JP, Wang F, Yang JJ, Sun F, Chen D, Lin L, He J: Factors affecting survival of hepatic carcinoma patients and their clinical significance (in Chinese). Chin J Oncol 1996;18:359–361.
3.
Yu YQ, Xu DB, Zhou XD, Lu JZ, Tang ZY, Mack P: Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993;71:62–65.
4.
Cheng LF, Wang ZQ, Cai FC, Zhang YH, Liu YD: Analysis of survival in 240 patients with unresectable primary hepatocellular carcinoma treated with hepatic artery chemoembolization (in Chinese). Chin J Oncol 1996;18:362–365.
5.
Arii S, Okamoto E, Imamura M: Registries in Japan: Current status of hepatocellular carcinoma in Japan. Semin Surg Oncol 1996;12:204–211.
6.
Group d’Etude et de Traitement du Carcinome Hépatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256–1261.
7.
Lehnert T, Herfarth C: Chemoembolization for hepatocellular carcinoma, what, when, and for whom? Ann Surg 1996;224:1–3.
8.
Wang YH, Lin YX, Feng YQ, Ji XL, Zhao HL: Secondary resection of primary liver carcinoma after transcatheter hepatic arterial embolization (TAE): Clinicopathological features and postoperative course of 33 cases (in Chinese). J Hepatobiliary Pancr Splenic Surg 1997;3:68–73.
9.
Tang ZY, Yu YQ, Zhou XD, Yang BH, Lin ZY, Lu JZ, Ma ZC, Ye SL, Liu KD: Three decades’ experience in surgery of hepatocellular carcinoma. Chin Med J 1997;110:245–249.
10.
Yu YQ, Tang ZY, Ma ZC, Zhou XD, Lu JZ: Resection of the primary liver tumour at the hepatic hilus. Cancer 1991;67:1322–1325.
11.
Tang ZY, Yu YQ, Zhou XD, Ma ZC, Yang R, Lu JZ, Lin ZY, Yang BH: Surgery of small hepatocellular carcinoma – Analysis of 144 cases. Cancer 1989;64:536–541.
12.
Farinati F, De Maria N, Marafin C, Herszenyi L, Del Prato S, Rinaldi M, Perini L, Cardin R, Naccarato R: Unresectable hepatocellular carcinoma in cirrhosis: Survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 1996;41:2332–2339.
13.
Liou TC, Shih SC, Kao CR, Chou SY, Lin SC, Wang HY: Pulmonary metastasis of hepatocellular carcinoma assoicated with transarterial chemoembolization. J Hepatol 1995;23:563–568.
14.
Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, Peng FK: Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal. Br J Surg 1995;82:122–126.
15.
Belli L, Magistetti G, Puricelli GP, Damiani G, Colombo E, Cornalba GP: Arteritis following intra-arterial chemotherapy for liver tumors. Eur Radiol 1997;7:323–326.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.